J-J Grob1, M M Amonkar2, S Martin-Algarra3, L V Demidov4, V Goodman2, K Grotzinger2, P Haney2, E Kämpgen5, B Karaszewska6, C Mauch7, W H Miller8, M Millward9, B Mirakhur2, P Rutkowski10, V Chiarion-Sileni11, S Swann2, A Hauschild12. 1. Aix-Marseille University, APHM, Hôpital Timone, Marseille, France jean-jacques.grob@ap-hm.fr. 2. GlaxoSmithKline, Collegeville, USA. 3. Department of Medical Oncology, Clínica Universidad de Navarra, Pamplona, Spain. 4. Department of Tumor Biotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation. 5. Department of Dermatology, Skin Cancer Center, University Hospital Erlangen, Erlangen, Germany. 6. Przychodnia Lekarska KOMED, Konin, Poland. 7. Department for Dermatology and Venereology and CIO KölnBonn, University Hospital Cologne, Cologne, Germany. 8. Departments of Oncology and Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, Canada. 9. Department of Medical Oncology, Sir Charles Gairdner Hospital and School of Medicine and Physiology, University of Western Australia, Perth, Australia. 10. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. 11. Melanoma Cancer Unit, Veneto Oncology Institute-IRCCS, Padova, Italy. 12. Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
Abstract
BACKGROUND: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAF V600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. METHODS: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. RESULTS: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. CONCLUSIONS: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient. ClinicalTrials.gov Identifier: NCT01227889.
RCT Entities:
BACKGROUND: In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95% confidence interval 0.18-0.53; P < 0.0001) compared with dacarbazine (DTIC) in patients with BRAFV600E metastatic melanoma. Assessing how these results are transformed into a real health benefit for patients is crucial. METHODS: The EORTC QLQ-C30 questionnaire assessed quality of life (QoL) at baseline and follow-up visits. RESULTS: For DTIC, all functional dimensions except role dimension worsened from baseline at follow-up. For dabrafenib, all functionality dimensions remained stable relative to baseline or improved at week 6; mean change in seven symptom dimensions improved from baseline, with appetite loss, insomnia, nausea and vomiting, and pain showing the greatest improvement. In the DTIC arm, symptom dimensions were unchanged or worsened from baseline for all symptoms except pain (week 6), with the greatest exacerbations observed for fatigue and nausea and vomiting. Mixed-model-repeated measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements from baseline in favor of dabrafenib for emotional and social functioning, nausea and vomiting, appetite loss, diarrhea, fatigue, dyspnea, and insomnia at weeks 6 and/or 12. After crossing over to dabrafenib upon progression (n = 35), improvements in all QoL dimensions were evident after receiving dabrafenib for 6 (n = 31) to 12 (n = 25) weeks. CONCLUSIONS: This first reported QoL analysis for a BRAF inhibitor in metastatic melanoma demonstrates that the high tumor response rates and PFS superiority of dabrafenib over DTIC is not only a theoretical advantage, but also transforms in a rapid functional and symptomatic benefit for the patient. ClinicalTrials.gov Identifier: NCT01227889.
Authors: Eva Muñoz-Couselo; Jesús Soberino García; José Manuel Pérez-García; Vanesa Ortega Cebrián; Javier Cortés Castán Journal: Ann Transl Med Date: 2015-09
Authors: Bruno Kovic; Xuejing Jin; Sean Alexander Kennedy; Mathieu Hylands; Michal Pedziwiatr; Akira Kuriyama; Huda Gomaa; Yung Lee; Morihiro Katsura; Masafumi Tada; Brian Y Hong; Sung Min Cho; Patrick Jiho Hong; Ashley M Yu; Yasmin Sivji; Augustin Toma; Li Xie; Ludwig Tsoi; Marcin Waligora; Manya Prasad; Neera Bhatnagar; Lehana Thabane; Michael Brundage; Gordon Guyatt; Feng Xie Journal: JAMA Intern Med Date: 2018-12-01 Impact factor: 21.873
Authors: Lawrence N Kwong; Genevieve M Boland; Dennie T Frederick; Timothy L Helms; Ahmad T Akid; John P Miller; Shan Jiang; Zachary A Cooper; Xingzhi Song; Sahil Seth; Jennifer Kamara; Alexei Protopopov; Gordon B Mills; Keith T Flaherty; Jennifer A Wargo; Lynda Chin Journal: J Clin Invest Date: 2015-02-23 Impact factor: 14.808
Authors: Federica Catalanotti; Donavan T Cheng; Alexander N Shoushtari; Douglas B Johnson; Katherine S Panageas; Parisa Momtaz; Catherine Higham; Helen H Won; James J Harding; Taha Merghoub; Neal Rosen; Jeffrey A Sosman; Michael F Berger; Paul B Chapman; David B Solit Journal: JCO Precis Oncol Date: 2017-06-23
Authors: G V Long; V Atkinson; P A Ascierto; C Robert; J C Hassel; P Rutkowski; K J Savage; F Taylor; C Coon; I Gilloteau; H B Dastani; I M Waxman; A P Abernethy Journal: Ann Oncol Date: 2016-07-12 Impact factor: 32.976
Authors: Anthony J Hatswell; Becky Pennington; Louisa Pericleous; Donna Rowen; Maximilian Lebmeier; Dawn Lee Journal: Health Qual Life Outcomes Date: 2014-09-10 Impact factor: 3.186